Взаимосвязь уровня липопротеин-ассоциированной фосфолипазы А2 с категориями риска сердечно-сосудистых осложнений и атеросклеротическим поражением сонных артерий - страница 9


  • Mockel M., Muller R. Lipoprotein-Associated Phospholipase A2 for Early Risk Stratification in Patients with Suspected Acute Coronary Syndrome: A Multi-Marker Approach: The North Wuerttemberg and Berlin Infarction Study-ll (NOBIS-II). Clin Res Cardiol. 2007; 96(9):604-612

  • Garza С.А., Montori V.M., Mcconnell J.P. Association Between Lipoprotein-Associated Phospholipase A2 and Cardiovascular Disease: A Systematic Review. Mayo Clin Proc. February 2007; 82(2):159-165

  • Angelantonio E.D., Gao P., Pennells L. et al. Lipid-Related Markers and Cardiovascular Disease Prediction. JAMA, 2012—Vol 307, No. 23, p. 2499-2506

  • Khot U.N., M Khot.B., C Bajzer.T., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290(7):898-904

  • Castelli W.P. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996; 124 Suppl:S1-9

  • Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Москва, 2012 г

  • Helfand М., et al. C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force Annals of Internal Medicine, 2009, October

  • BraunL.T., DavidsonM.H. Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep. 2010 Jan; 12(1):29-33

  • Wang Z.H., X Liu L, Zhong M., et al. Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. J Clin Pharmacol. 2010 Mar; 50(3):311-9. Epub 2009 Oct 6

  • KaralisI.K., Bergheanu S.C., Wolterbeek R., et al. Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. JCurr Med Res Opin. 2010 Oct;26(10):2301-13

  • Racherla S., Arora R. Utility of Lp-PLA2in Lipid-Lowering Therapy. Am J Ther. 2010 Jul 10

  • QiaoZ., Ren J., ChenH. Simvastatin reduces expression and activity of lipoprotein-associated phospholipase A(2) in the aorta of hypercholesterolaemic atherosclerotic rabbits. J Int Med Res. 2009 Jul-Aug; 37(4):1029-37

  • White H., Held C., Stewart R., et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J. 2010 Oct; 160(4):655-61

  • The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52)

  • Hatoum IJ, Nelson JJ, Cook NR. et al. Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr. 2010 Mar;91(3):786-93

  • Kaminsky LA, Ozemek C. Clin Biochem. 2012 Jun;45(9):700-2. Diurnal variation in lipoprotein-associated phospholipase A(2) (Lp-PLA(2))

  • Bekci TT, Kayrak M, Kiyici A. et al. The relation between Lp-PLA2 levels with periodic limb movements. Sleep Breath. 2012 Mar;16(1):117-22

  • Basu A, Jensen MD, McCann F. et al. Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes. Endocr Pract. 2007 Mar-Apr;13(2):147-52

  • Iwase M, Sonoki K, Sasaki N et al. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis. 2008 Feb;196(2):931-6

  • Noto H, Chitkara P, Raskin P. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. J Diabetes Complications. 2006 Nov-Dec;20(6):343-8

  • Hatoum IJ, Hu FB, Nelson JJ, Rimm EB. Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes. Diabetes. 2010 May;59(5):1239-43

  • Ostadal P., Vondrakova D., Kruger A., et al. Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers. Lipids Health Dis. 2012 Nov 10;11:153

  • Titov V.N., Urazalina C.Zh., Ameliushkina V.A., et al. Lipoprotein-associated phospholipase A2 in subjects at low and moderate risk estimated by the SCORE scale. Klin Med (Mosk). 2012;90(7):37-42

  • Lanman RB, Wolfert RL, Fleming JK. et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol. 2006 Summer;9(3):138-43

  • Constantinides A., de Vries R., van Leeuwen J.J., et al. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity. Eur J Intern Med. 2012 Oct;23(7):633-8

  • Ridker P.M., MacFadyen J.G., Wolfert R.L., Koenig W. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. Clin Chem. 2012 May;58(5):877-86

  • Stein E.A. Lipoprotein-associated phospholipase A₂ measurements: mass, activity, but little productivity. Clin Chem. 2012 May;58(5):814-7

  • Charniot J.C., Khani-Bittar R., Albertini J.P., et al. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments. Int J Cardiol. 2012 Oct 23. pii: S0167-5273(12)01160-6

  • Ryu S.K., Mallat Z., Benessiano J., et al. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation. 2012 Feb 14;125(6):757-66

  • Nelson T.L., Biggs M.L., Kizer J.R., et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study. J Clin Endocrinol Metab. 2012 May;97(5):1695-701

  • Kizer J.R., Umans J.G., Zhu J., et al. Lipoprotein-associated phospholipase A(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart Study. Diabetes Care. 2012 Apr;35(4):840-7

  • Wierzbicki A.S. New directions in cardiovascular risk assessment: the role of secondary risk stratification markers. Int J Clin Pract. 2012 Jul;66(7):622-30

  • Catapano A., Reiner Z., de Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force on the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011

  • Sarlon-Bartoli G., Boudes A., Buffat C., et al. Circulating lipoprotein-associated phospholipase A2 in high-grade carotid stenosis: a new biomarker for predicting unstable plaque. Eur J Vasc Endovasc Surg. 2012 Feb;43(2):154-9

  • Vickers K.C., Maguire C.T., Wolfert R., et al. Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis. J Lipid Res. 2009 Sep;50(9):1735-43

  • Epps K.C., Wilensky R.L. Lp-PLA₂- a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med. 2011 Jan;269(1):94-106

  • Kardys I., Oei H.H., van der Meer I.M., et al. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):631-6

  • Dohi T., Miyauchi K., Okazaki S., et al. Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome. Atherosclerosis. 2011 Dec;219(2):907-12

    4 5 6 7 8 9 Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат
    Реферат